Dyne Therapeutics, Inc. ( DYN) Stock. Should you Buy or Sell? $ 14.91
0.02 (0.13 %)
Dyne Therapeutics, Inc. Analysis
Updated on 10-09-2022| Symbol | DYN |
| Price | $14.91 |
| Beta | 1.604 |
| Volume Avg. | $232.5 thousand |
| Market Cap | $771.82 M |
| 52 Week Range | $4.3 - $17.89 |
Dyne Therapeutics, Inc. opened the day at $14.91 which is +'0.13 % on yesterday's close. Dyne Therapeutics, Inc. has a 52 week high of $17.89 and 52 week low of $4.3, which is a difference of $13.59. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $771.82 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Dyne Therapeutics, Inc. for $771.82 M, it would take 15 years to get your money back. Dyne Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Dyne Therapeutics, Inc. Stock Forecast - Is Dyne Therapeutics, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -4.228 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Dyne Therapeutics, Inc.
| Price Book Value Ratio | 2.684 | Price To Book Ratio | 2.684 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -4.228 |
How liquid is Dyne Therapeutics, Inc.
| Current Ratio | 11.628 |
| Quick Ratio | 11.390 |
Debt
| Debt Ratio | 0.156 | Debt Equity Ratio | 0.185 |
| Long Term Debt To Capitalization | 0.087 | Total Debt To Capitalization | 0.103 |
Latest news about Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference being held in New York, NY on Monday, September 12, 2022 at 2:15 p.m. ET.
Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ: RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ: DYN) with a Buy rating and a price target of $17. "We believe that Avidity and Dyne are an.
Dyne Therapeutics Inc (NASDAQ: DYN) shares are trading lower by 5.42% to $6.81 after the company announced FDA clearance of its Investigational New Drug application for DYNE-251 for the treatment of Duchenne muscular dystrophy. Dyne says the company plans to evaluate DYNE-251 in a global,.
WALTHAM, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 9, 2022 at 3:00 p.m. ET.
A clinical hold regarding one of the company's therapies brought Dyne's shares to a 52-week low.
About Dyne Therapeutics, Inc.
Description :
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
